DCN – The Advanced Lateral Flow Course – we’ll help you develop your LFA!

DCN – The Advanced Lateral Flow Course (ALFC) is a three-day lateral flow seminar aimed at developers and manufacturers of rapid diagnostic tests and their associated products. During this seminar, some of the most experienced professionals in the diagnostics industry will guide you through the steps of producing and commercializing a point of care diagnostic device.

When: 22-24 October 2019
Where: Westin San Diego Gaslamp, USA
Booth: 6

We will be showcasing solutions for your lateral flow assay development:

Our team of experts will be on hand to answer your questions about our products and services that can assist you and your team in your laboratory research.

Enhance the signal on your LFA with our Colloidal Gold Nanoparticles:
Expedeon colloidal gold is developed using specialized techniques that enable the production of extremely uniform spherical particles with a very narrow size distribution, minimizing variability within your assay.
Our colloidal gold is available in various sizes, concentrations, and volumes for maximum flexibility.

Discover the power of Lightning-Link:
An innovative technology that enables direct labeling of antibodies or proteins for use in R&D applications, drug discovery and the development of diagnostic kits.

Meet our Universal Lateral Flow Assay Kit:
Expedeon’s Universal Lateral Flow Assay (LFA) Kit is designed to enable the easy development of customized sandwich lateral flow assays. The great advantage of this kit is its adaptability to any pair of capture and detection antibodies, which allows the detection of any type of analyte* without the need to spray down capture antibodies on the test strip, a labor-intensive process that consumes large amounts of expensive antibody reagent.

If you would like to set up a meeting whilst at the event please email us at solutions@expedeon.com

For more information on the event please visit The Advanced Lateral Flow Course website here.

Your preferred local currency is now